Bio Pro Classes:

 
Tuesday, 17 May 2016 - Wednesday, 29 Jun 2016
Category: Bio Pro Classes

 
Monday, 13 Jun 2016 - Wednesday, 15 Jun 2016
Category: Bio Pro Classes

 
Monday, 20 Jun 2016
Category: Bio Pro Classes

 
Monday, 25 Jul 2016 - Tuesday, 26 Jul 2016
Category: Bio Pro Classes

 
Monday, 01 Aug 2016 - Tuesday, 02 Aug 2016
Category: Bio Pro Classes

Event Registration Cart

Your cart is empty.

 SBIR 101: How to create a competitive SBIR grant application.

 

Dr FarellThis is a must attend event for any entrepreneur trying to pursue SBIR and other forms of government grant funding. Dr. David Farrell will share decades of experience successfully soliciting federal grants (SBIR, STTR, etc.) from the federal government. Unlike other seminars and workshops, Dr. Farrell takes a hands on approach. From teaching you the history of the programs, to actually logging onto the relevant sites and completing registration forms, participants complete the practical steps necessary to jumpstart their submissions.

 

Dr. Farrell's workshop will cover the broadest spectrum of federal programs, including SBIR/STTR programs for the National Science Foundation (NSF), United States Department of Agriculture (USDA), and the Environmental Protection Agency (EPA), with an emphasis on the National Institutes of Health (NIH). In addition, the huge Department of Defense budget will also be explored, including a few little-known pots of money--including: the Congressionally Directed Medical Research Programs (CDMRP), Air Force, Defense Advanced Research Projects Agency (DARPA), Navy, Defense Threat Reduction Agency (DTRA), and Army SBIR/STTR programs and other non-SBIR contract programs.

 

This interactive session will include attendees downloading onto their own laptops each of the subsections of the application forms while Dr. Farrell explains proven strategies for creating competitive applications. This class is focused on overcoming the barriers standing between you and a funded grant.

 

News Flash

  • BIO Releases Largest Ever Study on Clinical Development Success Rates

    WASHINGTON--(BUSINESS WIRE)--Today, the Biotechnology Innovation Organization (BIO) released the largest ever study of clinical development success rates. The study, conducted in partnership with Amplion and Biomedtracker, recorded and analyzed 9,985 clinical and regulatory phase transitions, across 1,103 companies. Using clinical trial data from the past decade, “Clinical Development Success Rates 2006-2015” compares groups of diseases, drug modalities and other attributes to generate the most comprehensive analysis, to date, of biopharmaceutical R&D success.

    “This study provides a wealth of information about drug development success rates across a broad range of indications,” said Cartier Esham, PhD, BIO’s Executive Vice President, Emerging Companies. “The results may be used to pinpoint disease areas and phases of development where the industry has been most successful in recent years, as well as areas presenting challenges along the capital intensive-pathway of drug development.”

    Key findings from the study include:
    • Clinical trial programs that used selection biomarkers saw an overall likelihood of approval (LOA) from Phase I of 25.9%, compared to 8.4% when no selection biomarkers were used.
    • The overall LOA from Phase I for all developmental candidates was 9.6%, and 11.9% for all indications outside of Oncology.
    • Of the 14 major disease areas studied, Hematology had the highest LOA from Phase I (26.1%) and Oncology had the lowest (5.1%).
    • Oncology drugs were approved the fastest of all 14 disease areas.
    • Rare disease programs had higher success rates at each phase of development vs. the overall dataset.
    • Chronic diseases with high populations had lower LOA from Phase I vs. the overall dataset.
    The study relied upon years of clinical program monitoring and data entry by Informa’s Biomedtracker service. BIO has long partnered with Biomedtracker to calculate success rates based on this data. More recently, BIO and Biomedtracker partnered with Amplion, the inventors of BiomarkerBase, to analyze the effects of biomarkers in clinical trial success.

    “Combining Amplion’s biomarker database with Biomedtracker’s clinical transition records we were able to, for the first time, quantify the benefit of using selection biomarkers in drug development,” said study author David Thomas, CFA, BIO’s Senior Director of Industry Research. “In combination with the rare disease section of the report, these results appear to be revealing the overall strength in targeting well-defined, homogenous patient populations.”

    A full version of the report is available for download here.

    Thomas will be discussing the report on June 6 at the 2016 BIO International Convention during his session, "The State of the Innovation Industry.
    __________________________________

    May 25, 2016

Bioscience News

  • On Wednesday, BIO released the largest ever study of clinical development success rates. The study, conducted in partnership with Amplion and Biomedtracker, recorded and analyzed 9,985 clinical and regulatory phase transitions, across 1,103 companies. Using clinical trial data from the past decade, “Clinical Development Success Rates 2006-2015” compares groups of diseases, drug modalities and other attributes to generate the most comprehensive analysis, to date, of biopharmaceutical R&D success. “This study provides a wealth of information about drug development success rates Read More >

  • This morning, in a letter to the editor of the New York Times, Marilyn Tavenner, President and CEO of America’s Health Insurance Plans (AHIP), attempted to lay the blame for higher healthcare costs and insurance premiums at the feet of America’s cutting-edge biopharma companies. AHIP has been peddling these falsehoods and misinformation for years.  Tavenner’s (and her organization’s) claims are—at best—uninformed. At worst, they are outright distortions deployed to hide the facts from patients who Read More >

  • “40% of food grown in U.S. is wasted.” – House Ag Commitee Chairman Conaway On Wednesday, May 25, 2016, the House Committee on Agriculture held a hearing to examine what voluntary efforts can be done to address the issue of food waste. The hearing was titled Food Waste from Field to Table and witnesses included Rep. Chellie Pingree (D-Maine), along with several other experts on the issue. Ms. Dana Gunders, Senior Scientist, Food & Agriculture Program, National Resources Defense Read More >

joomla social media module

Underwriting Sponsors

Sustaining Sponsors

Principal Sponsors

Home | Bio in Oregon | BioPro Training | Events | Sponsors | Member Resources | News | About Us

Oregon Bioscience Association Copyright © 2016. All Rights Reserved.

javddt comicsbb.com